All Stories

  1. Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?

    Article • Journal of Comparative Effectiveness Research, September 2017, Future Medicine

    Dr José A Sacristán

  2. Patient involvement in clinical research: why, when, and how

    Article • Patient Preference and Adherence, April 2016, Dove Medical Press

    Dr José A Sacristán, Dr PILAR GARRIDO, Mr Alfonso Aguarón

  3. The value of innovation in oncology

    Article • Patient Preference and Adherence, December 2015, Dove Medical Press

    Professor Luis Lizan, Dr Silvia Paz, Dr PILAR GARRIDO, Dr José A Sacristán

  4. Patients’ Preferences for Rheumatoid Arthritis Treatments and their Participation in the Treatment Decision-Making Process. A Systematic Review of the Literature

    Article • Value in Health, November 2015, Elsevier

    Dr José A Sacristán

  5. Where is the person in precision medicine?

    Article • Journal of Evaluation in Clinical Practice, September 2015, Wiley

    Dr José A Sacristán

  6. Do new Cancer drugs offer good value for Money? the perspective of oncologists, payers, patients, and general Population

    Article • Clinical Therapeutics, August 2015, Elsevier

    Dr José A Sacristán

  7. No big data without small data: learning health care systems begin and end with the individual patient

    Article • Journal of Evaluation in Clinical Practice, March 2015, Wiley

    Dr José A Sacristán

  8. Educación Médica: una nueva etapa

    Article • Educación Médica, January 2015, Elsevier

    Dr José A Sacristán

  9. Clinical research and medical care: towards effective and complete integration

    Article • BMC Medical Research Methodology, January 2015, Springer Science + Business Media

    Dr José A Sacristán

  10. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison

    Article • BMC Psychiatry, December 2014, Springer Science + Business Media

    Dr José A Sacristán

  11. Value-based pricing: ¿nos enfrentamos a un nuevo paradigma?

    Article • PharmacoEconomics Spanish Research Articles, October 2014, Springer Science + Business Media

    Dr José A Sacristán

  12. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients

    Article • BMC Medical Informatics and Decision Making, January 2013, Springer Science + Business Media

    Dr José A Sacristán

  13. Priorización de intervenciones sanitarias en función de su efectividad: un paso intermedio en el camino hacia una medicina más eficiente

    Article • Medicina Clínica, October 2012, Elsevier

    Dr José A Sacristán

  14. Which Nontraditional Outcomes Should Be Measured in Healthcare Decision-Making in Schizophrenia? A Systematic Review

    Article • Perspectives In Psychiatric Care, February 2012, Wiley

    Dr José A Sacristán

  15. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain

    Article • Frontiers in Genetics, January 2012, Frontiers

    Dr José A Sacristán

  16. A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus

    Article • Clinical Therapeutics, September 2011, Elsevier

    Dr José A Sacristán

  17. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus

    Article • Endocrinología y Nutrición (English Edition), August 2011, Elsevier

    Dr José A Sacristán

  18. Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España

    Article • Endocrinología y Nutrición, August 2011, Elsevier

    Dr José A Sacristán

  19. Medicina centrada en el paciente e investigación de la efectividad comparada

    Article • Medicina Clínica, April 2011, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  20. Exploratory trials, confirmatory observations: A new reasoning model in the era of patient-centered medicine

    Article • BMC Medical Research Methodology, January 2011, Springer Science + Business Media

    Dr José A Sacristán

  21. Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses

    Article • JAMA, April 2010, American Medical Association (AMA)

    Dr José A Sacristán, Dr José Antonio Sacristán

  22. Health economics: the start of clinical freedom

    Article • BMC Health Services Research, January 2010, Springer Science + Business Media

    Dr José A Sacristán

  23. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

    Article • BMC Cancer, January 2010, Springer Science + Business Media

    Dr José A Sacristán

  24. PMC2 A STANDARDIZED EVIDENCE BASED APPROACH TO ASSESS NONTRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE DECISION MAKING: THE DIABETES EXAMPLE

    Article • Value in Health, October 2009, Elsevier

    Dr José A Sacristán

  25. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora

    Article • Atención Primaria, June 2009, Elsevier

    Dr José A Sacristán

  26. Reflexiones sobre reglas de decisión, coste-efectividad e impacto presupuestario

    Article • Gaceta Sanitaria, December 2008, Elsevier

    Dr José A Sacristán

  27. Evaluación económica de medicamentos: experiencias y vías de avance

    Article • Gaceta Sanitaria, July 2008, Elsevier

    Dr José A Sacristán

  28. PMH27 COST-EFFECTIVENESS OF DULOXETINE VS. VENLAFAXINE XRAND SSRIS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN PRIMARY AND SECONDARY CARE IN SPAIN

    Article • Value in Health, November 2007, Elsevier

    Dr José A Sacristán

  29. Los medicamentos en la Unión Europea: el tándem comercio-salud

    Article • Gaceta Sanitaria, April 2005, Elsevier

    Dr José A Sacristán

  30. Réplica

    Article • Gaceta Sanitaria, November 2004, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  31. Cartas al Editor

    Article • Medicina Clínica, October 2004, Elsevier

    Dr José A Sacristán

  32. Réplica

    Article • Medicina Clínica, October 2004, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  33. Análisis de la incertidumbre en las evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, May 2004, Elsevier

    Dr José A Sacristán

  34. Utilización de las evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, May 2004, Elsevier

    Dr José A Sacristán

  35. PMD23 WHAT IS THE VALUE OF SOCIAL VALUES? THE USELESSNESS OF ASSESSING HEALTH-RELATED QUALITY OF LIFE THROUGH PREFERENCE MEASURES

    Article • Value in Health, May 2004, Elsevier

    Dr José A Sacristán

  36. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias

    Article • Medicina Clínica, April 2004, Elsevier

    Dr José A Sacristán

  37. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, April 2004, Elsevier

    Dr José A Sacristán

  38. Evaluación económica en medicina

    Article • Medicina Clínica, March 2004, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  39. Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias

    Article • Medicina Clínica, March 2004, Elsevier

    Dr José A Sacristán

  40. Evaluación económica en medicina

    Article • Medicina Clínica, January 2004, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  41. Réplica

    Article • Gaceta Sanitaria, January 2004, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  42. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias

    Article • Medicina Clínica, January 2004, Elsevier

    Dr José A Sacristán

  43. Análisis de la incertidumbre en las evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, January 2004, Elsevier

    Dr José A Sacristán

  44. Utilización de las evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, January 2004, Elsevier

    Dr José A Sacristán

  45. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias

    Article • Medicina Clínica, January 2004, Elsevier

    Dr José A Sacristán

  46. Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España

    Article • Gaceta Sanitaria, January 2004, Elsevier

    Dr José A Sacristán

  47. Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España

    Article • Gaceta Sanitaria, January 2004, Elsevier

    Dr José A Sacristán

  48. PMD41 THE NATURE OF THE QUALITY-ADJUSTED LIFE YEAR (QALY) CALCULATION

    Article • Value in Health, November 2003, Elsevier

    Dr José A Sacristán

  49. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    Article • European Neuropsychopharmacology, January 2003, Elsevier

    Dr José A Sacristán

  50. PIN4 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN

    Article • Value in Health, November 2002, Elsevier

    Dr José A Sacristán

  51. Global index of safety (GIS)

    Article • Journal of Clinical Epidemiology, November 2001, Elsevier

    Dr José A Sacristán

  52. "Dr. Sacristan and Colleagues Reply"

    Article • The Journal of Clinical Psychiatry, October 2001, Physicians Postgraduate Press, Inc

    Dr José A Sacristán, Dr José Antonio Sacristán

  53. Protocolos de uso compasivo y Comités Éticos de Investigación Clínica

    Article • Medicina Clínica, January 2001, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  54. Dr. Sacristán replies:

    Article • Clinical Therapeutics, November 2000, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  55. PNH6: ANTIPSYCHOTIC TREATMENT, ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE

    Article • Value in Health, September 2000, Elsevier

    Dr José A Sacristán

  56. PMH10: SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC TREATMENT AND COMPLIANCE IN SCHIZOPHRENIA

    Article • Value in Health, September 2000, Elsevier

    Dr José A Sacristán

  57. PMH3: GLOBAL INDEX OF SAFETY (GIS): A NEW INSTRUMENT TO ASSESS DRUG SAFETY: APPLICATION TO A PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY (EFESO)

    Article • Value in Health, September 2000, Elsevier

    Dr José A Sacristán

  58. Comparative pharmacoeconomic study of vancomycin and teicoplanin in intensive care patients

    Article • International Journal of Antimicrobial Agents, June 2000, Elsevier

    Dr José A Sacristán

  59. The Safety of Olanzapine Compared With Other Antipsychotic Drugs

    Article • The Journal of Clinical Psychiatry, May 2000, Physicians Postgraduate Press, Inc

    Dr José A Sacristán

  60. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study

    Article • Clinical Therapeutics, May 2000, Elsevier

    Dr José A Sacristán

  61. PCN2: DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE: RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO)

    Article • Value in Health, September 1999, Elsevier

    Dr José A Sacristán

  62. QL3: ANTIPSYCHOTIC TREATMENT AND CHANGES IN HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA USING EQ-5D

    Article • Value in Health, September 1999, Elsevier

    Dr José A Sacristán

  63. Clinical trials

    Article • BMJ, April 1999, BMJ

    Dr José A Sacristán, Dr José Antonio Sacristán

  64. Antidepressant Use and Clinical and Economic Outcomes in a Primary Care Psychiatry Center in Spain

    Article • January 1999, Springer Science + Business Media

    Dr José A Sacristán

  65. SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study

    Article • Journal of Affective Disorders, January 1999, Elsevier

    Dr José A Sacristán

  66. Effectiveness and Cost of Selective Decontamination of the Digestive Tract in Critically Ill Intubated Patients

    Article • American Review of Respiratory Disease, September 1998, American Thoracic Society

    Dr José A Sacristán

  67. Large-Database Research: Complement to Randomized Trials?

    Article • Annals of Internal Medicine, May 1998, American College of Physicians

    Dr José A Sacristán

  68. MHA4 SSRI Antidepressant Use Patterns and their Relation to Clinical Global Impressions Scores: A Naturalistic Study

    Article • Value in Health, May 1998, Elsevier

    Dr José A Sacristán

  69. Patterns of antidepressant use and their relation to clinical global impression scores

    Article • European Psychiatry, January 1998, Elsevier

    Dr José A Sacristán

  70. The Negative Side of Cost-effectiveness Analysis-Reply

    Article • JAMA, June 1997, American Medical Association (AMA)

    Dr José A Sacristán

  71. Reporting cost-effectiveness analyses with confidence

    Article • JAMA, February 1997, American Medical Association (AMA)

    Dr José A Sacristán

  72. Principles of Economic Analysis of Health Care Technology

    Article • Annals of Internal Medicine, March 1996, American College of Physicians

    Dr José A Sacristán

  73. Bias in assignment to clinical trials

    Article • BMJ, April 1994, BMJ

    Dr José A Sacristán

  74. Drug Utilisation Studies as Tools in Health Economics

    Article • PharmacoEconomics, April 1994, Springer Science + Business Media

    Dr José A Sacristán

  75. Monitoring theophylline treatment.

    Article • BMJ, February 1993, BMJ

    Dr José A Sacristán

  76. Terfenadine-Induced tremor

    Article • Annals of Neurology, February 1993, Wiley

    Dr José A Sacristán

  77. Erythromycin ototoxicity: Methodology and conclusions

    Article • The American Journal of Medicine, February 1993, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  78. "Economic relevance" in pharmacoeconomic studies.

    Article • BMJ, January 1993, BMJ

    Dr José A Sacristán

  79. Probable Acenocoumarol-Amoxycillin Interaction

    Article • Acta Haematologica, January 1993, Karger Publishers

    Dr José A Sacristán

  80. Pulmonary oedema due to fentanyl?

    Article • Anaesthesia, October 1992, Wiley

    Dr José A Sacristán

  81. Complacency bias in clinical trials

    Article • The Lancet, August 1992, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  82. Vancomycin peak concentration and ototoxicity prevention

    Article • Journal of Antimicrobial Chemotherapy, January 1992, Oxford University Press (OUP)

    Dr José A Sacristán, Dr José Antonio Sacristán

  83. Effect of Carbamazepine on Ciclosporin Blood Level

    Article • January 1991, Karger Publishers

    Dr José A Sacristán

  84. Erythromycin-induded hearing loss

    Article • The Lancet, October 1990, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán

  85. Immediate hypersensitivity to aztreonam

    Article • The Lancet, May 1990, Elsevier

    Dr José A Sacristán, Dr José Antonio Sacristán